Human monoclonals against erythrocyte antigens.

Area of Science:

• Immunology
• Hematology
• Biotechnology

Background:

• Mice cannot produce specific antibodies against human Rh-D antigen, limiting diagnostic tools.
• Existing murine monoclonal antibodies against Rh-proteins lack specificity for routine blood grouping.
• Human immune responses generate specific anti-Rh-D alloantibodies.

Purpose of the Study:

• To establish efficient protocols for producing human monoclonal antibodies against the Rh-D antigen.
• To compare various methods for generating human monoclonal antibodies against Rh-D.
• To identify optimal fusion partners and immortalization techniques for Rh-D antibody production.

Main Methods:

• Evaluated direct fusion of human peripheral blood lymphocytes (PBL) with myeloma or lymphoblastoid cell lines.
• Assessed Epstein-Barr virus (EBV) transformation of PBL for immortalization.
• Compared EBV-transformed PBL fusions with mouse myeloma (P3X63-Ag8.653) and heteromyeloma (MD33) lines.

Main Results:

• EBV-transformation followed by fusion with mouse myeloma or heteromyeloma lines yielded the most successful outcomes.
• Several stable, antigen-specific human monoclonal antibody lines against Rh-D were generated per fusion.
• The heteromyeloma line MD33 demonstrated a high fusion rate and hybridoma production.

Conclusions:

• Fusion of EBV-transformed human PBL with specific mouse myeloma or heteromyeloma lines is highly effective for producing anti-Rh-D monoclonal antibodies.
• This approach overcomes previous limitations in generating specific human antibodies for blood grouping.
• The developed protocols offer a reproducible method for obtaining valuable diagnostic reagents.